However, similar to our findings, Landre et al. indicated that NSCLC patients older than 75 years had an inferior OS compared with those of a younger age when treated with anti‐PD‐1 inhibitors.27 This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.